Human papillomavirus seroprevalence among young male and female drug users

Sexually Transmitted Diseases

Volumn 34, Issue 9, 2007, Pages 676-680

  Plitt, Sabrina S ^a   Sherman, Susan G ^a   Viscidi, Raphael P ^b   Strathdee, Steffanie A ^c   Fuller, Crystal M ^d   Taha, Taha E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; ANAL SEX; ARTICLE; BEHAVIOR; COMPARATIVE STUDY; COMPREHENSION; CORRELATION FUNCTION; DRUG USE; EXPOSURE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 53; INJECTION; LOGISTIC REGRESSION ANALYSIS; MALE; RANK SUM TEST; RESEARCH; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEROPREVALENCE; SEX; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRUS STRAIN; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADULT; AGE FACTORS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; NEW YORK; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34548160492     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000258309.42765.ac     Document Type: Article

References (36)

1. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Am Social Health Association Panel. Sex Transm Dis 1999; 26(4 Suppl):S2-S7.
2. Koutsky LA, Kiviat N. Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases, 3rd ed., New York: McGraw-Hill, 1999: 347-359.
3. Kiviat N, Koutsky LA, Paavonen J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases, 3rd ed., New York: McGraw-Hill, 1999: 811-831.
4. Stone KM, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186:1396-1402.
5. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997; 176:876-883.
6. Slavinsky J III, Kissinger P, Burger L, et al. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 2001; 12:516-523.
7. Kreimer AR, et al. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004; 31:247-256.
8. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194:1044-1057.
9. Institute of Medicine, The Hidden Epidemic: Confronting Sexually Transmitted Diseases, Eng TR, Butler WT, eds. Washington, DC: National Academy Press, 1997.
10. Kral AH, Lorvick J, Edlin, BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24:162-167.
11. Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992; 18:263-273.
12. Chitwood DD, Comerford M, Kitner KR, et al. A comparison of HIV risk behaviors between new and long-term injection drug users. Subst Use Misuse 2001; 36:91-111.
13. Plitt SS, Sherman SG, Strathdee SA, et al. Herpes simplex virus 2 and syphilis among young drug users in Baltimore, Maryland. Sex Transm Infect 2005; 81:248-253.
14. Sanchez J, Comerford M, Chitwood DD, et al. High risk sexual behaviours among heroin sniffers who have no history of injection drug use: Implications for HIV risk reduction. AIDS Care 2002; 14:391-398.
15. Bosch F, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
16. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
17. Fuller CM, Vlahov D, Ompad DC, et al. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: A case-control study. Drug Alcohol Depend 2002; 66:189-198.
18. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89:1248-1254.
19. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9:423-430.
20. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12:485-490.
21. Thompson DL, Douglas JM Jr, Foster M, et al. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004; 190:1563-1574.
22. Poulin C, Alary M, Bernier F, et al. Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and HIV infection among drug users attending an STD/HIV prevention and needle-exchange program in Quebec City, Canada. Sex Transm Dis 1999; 26:410-420.
23. Hwang LY, Ross MW, Zack C, et al. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin Infect Dis 2000; 31:920-926.
24. McCoy CB, Metsch LR, Chitwood DD, et al. Drug use and barriers to use of health care services. Subst Use Misuse 2001; 36:789-806.
25. Holly EA, Ralston ML, Darragh TM, et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93:843-849.
26. Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2002, Bethesda, MD: National Cancer Institute; 2003.
27. Viscidi RP, Kotloff KL, Clayman B, et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997; 4:122-126.
28. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
29. Halperin DT. Heterosexual anal intercourse: Prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 1999; 13:717-730.
30. Moscicki AB, Hills NK, Shiboski S, et al. Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev 1999; 8:173-178.
31. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005; 14:2550-2556.
32. Misegades L, Page-Shafer K, Halperin D, et al. Anal intercourse among young low-income women in California: An overlooked risk factor for HIV? Aids 2001; 15:534-535.
33. Bell AV, Ompad D, Sherman SG. Sexual and drug risk behaviors among recent, former, and never WSW. Am J Public Health, 2006; 96:1066-1072.
34. Diaz T, Vlahov D, Greenberg B, et al. Sexual orientation and HIV infection prevalence among young Latino injection drug users in Harlem. J Womens Health Gend Based Med 2001; 10:371-380.
35. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16,18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-1919.
36. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174:927-936.